Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer.

摘要: Abstract Background Erlotinib is a key therapy for advanced NSCLC. Concurrent AS with TKIs might reduce TKI plasma levels. Because of gastroesophageal reflux disease prevalence, this retrospective analysis was undertaken to determine if coadministering erlotinib affected NSCLC outcomes. Patients and Methods Records patients who received from 2007 2012 at large, centralized, cancer institution were retrospectively reviewed. Pertinent demographic data collected concomitant treatment defined as prescription dates overlapping with ≥ 20% duration. for ≥ 1 week analyzed progression-free survival (PFS) overall (OS). Results Stage IIIB/IV (n = 544) identified 507 had adequate review. The median age 64 years 272 female. Adenocarcinoma 318; 64%) squamous 106; 21%) predominant subtypes; 124 therapy. In unselected population, PFS OS in versus no groups 1.4 2.3 months ( P  = .003), respectively. Factoring sex, subtype, performance status multivariate Cox proportional hazards ratios between 1.83 (95% confidence interval [CI], 1.48-2.25) 1.37 CI, 1.11-1.69), Conclusion This large population-based study suggests efficacy be linked gastric pH could adversely affected. To our knowledge, the first demonstrating possible negative clinical effect coadministration Further prospective investigation warranted.